Five Prime Therapeutics : Corporate Overview February 2020

Rewriting Cancer, Together

February 2021

fiveprime.com | NASDAQ: FPRX

Forward-Looking Statements Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. These forward-looking statements reflect Five Prime's current beliefs and expectations. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ from these forward-looking statements. Forward-looking statements contained in this presentation include statements about (i) the timing of initiation, progress and scope of clinical trials for Five Prime's product candidates; (ii) the timing and progress of preclinical activities for FPA157; (iii) the potential use of Five Prime's product candidates, including in combination with other products, to treat patients; (iv) the potential development of bemarituzumab in indications in addition to gastric and gastroesophageal cancer; (v) the timing of the presentation of data for Five Prime's product candidates; (vi) the extent of protein overexpression and gene amplification in certain patient populations; and (vii) Five Prime's potential receipt of milestone payments and royalties. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates, changes in the regulatory, pricing or reimbursement environment and unexpected litigation or other disputes. In addition, while we expect the COVID-19 pandemic to adversely affect our business operations and financial results, the extent of the impact on our ability to advance our manufacturing, clinical development and regulatory efforts and business and corporate development and other objectives and the value of and market for our common stock will depend on future developments that are highly uncertain, and we cannot predict with confidence the ultimate duration of the p andemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries and the effectiveness of actions taken globally to contain and treat COVID-19. Other factors that may cause our actual results to differ from current expectations are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, we assume no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Let's Rewrite Cancer, Together

Diversified portfolio of targeted and immuno-oncology therapies in clinical and preclinical development

Highly effective R&D organization

Track record of innovation

Significant cash balance and potential

financial upsides

At Five Prime, We Explore Untapped Pathways to Deliver Breakthrough Treatments

*Five Prime granted an exclusive license to Zai Lab to develop bemarituzumab in Greater China.